Format

Send to

Choose Destination
Cureus. 2018 Jul 5;10(7):e2924. doi: 10.7759/cureus.2924.

Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion.

Author information

1
Medicine, Jersey Shore University Medical Center, Neptune City, USA.

Abstract

Low dose naltrexone (LDN) has been promising as a complementary medication for patients with a broad range of medical disorders. Although not a proven cure, evidence from clinical trials supports LDN as being a valuable adjunct for disorders in which the immune system plays a centralized role. Additionally, clinical trials have proposed a unique mechanism(s) allowing LDN to affect tumors including non-small cell lung cancer (NSCLC) at the cellular level by augmenting the immune system. We present a case of a 50-year-old male with a prolonged survival and a past medical history of prostate and lung cancer.

KEYWORDS:

autoimmune disorders; chron's disease; endorphins; human immunodeficiency virus; low dose naltrexone; metkephalin; neurodegenerative conditions; non-small cell lung cancer; proclaim trial

Conflict of interest statement

The authors have declared that no competing interests exist.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center